

**LUMASON®**

(sulfur hexafluoride lipid-type A microspheres)  
for injectable suspension, for intravenous  
use or intravesical use  
**VISUALLY DECISIVE**

# 2024 REIMBURSEMENT RESOURCE KIT HOPPS

HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM

January 2024

## DISCLAIMERS

The information provided here is general reimbursement information for LUMASON. It is not legal advice, nor is it advice about how to code, complete, or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider's responsibility to determine and submit appropriate codes, charges, modifiers, and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.

CPT® copyright 2023 American Medical Association (AMA). All rights reserved. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

UNLOCKING THE  
**INVISIBLE**



## **Indications for LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use**

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

## **IMPORTANT SAFETY INFORMATION**

### **WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

**Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.**

- **Assess all patients for the presence of any condition that precludes administration**
- **Always have resuscitation equipment and trained personnel readily available**

### **Contraindications**

LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is contraindicated in patients with known or suspected hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG).

### **Warnings**

**Serious cardiopulmonary reactions**, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including LUMASON. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to LUMASON administration and monitor all patients for acute reactions.

Post-marketing **hypersensitivity reactions**, including serious hypersensitivity reactions, have been observed during use or shortly following LUMASON administration. These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid-containing microspheres. LUMASON contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG.

**Systemic embolization** may occur in patients with cardiac shunts. Assess patients with cardiac shunts for embolic phenomena following LUMASON administration.

There is a risk of **ventricular arrhythmia related to high mechanical index** in patients administered LUMASON. LUMASON is not recommended for use at mechanical indices greater than 0.8.

The most common adverse reactions (incidence  $\geq 0.5\%$ ) are headache (1%) and nausea (0.5%).

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.**

**Please [click here](#) to see full Prescribing Information for LUMASON ultrasound contrast agent, including BOXED WARNING on Serious Cardiopulmonary Reactions.**

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON and SONOVUE are registered trademarks of Bracco Diagnostics Inc. and its affiliated entities.

<b>Indications</b>	4
<b>Coding Nomenclature</b>	5
<b>Coding Information</b>	6
<b>Example of Billing</b>	7
<b>Medicare National Average Payment Rates</b>	8
<b>Hospital In-Patient Billing and Coverage</b>	11
<b>Ordering Information</b>	12
<b>Reimbursement Hotline</b>	13
<b>References</b>	14

**LUMASON® is the only ultrasound enhancing agent (UEA) with 3 indications¹**

- ✓ Echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
- ✓ Ultrasonography of the liver for the characterization of focal liver lesions in adult and pediatric patients
- ✓ Ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients



**All-inclusive portable kit**



**20 vials & 20 spike pack**

**UNLOCKING THE  
INVISIBLE**

## **CPT® (Current Procedural Terminology)**

Codes used to report the service or procedure performed.

## **HCPCS (Healthcare Common Procedure Coding System)**

Codes used to report the provision of supplies, materials, injections, and certain services and procedures. For example, the HCPCS code for LUMASON ultrasound enhancing agent (UEA) is Q9950.

## **C-codes**

Unique, temporary HCPCS codes created by Medicare and used for HOPPS only. This is often done when no other appropriate code exists. An example of this is the C-code series in echocardiography, which are described on page 8.

## **Coding Modifiers**

Under HOPPS, LUMASON UEA is not separately reimbursable, and therefore the JZ and JW Modifiers do not apply under this billing system. They are required for independent imaging centers billing under the Medicare Physician Fee Schedule.

## **ICD-10 (International Classification of Disease)**

Codes used to describe a patient's signs and symptoms that would represent a medically necessary reason for performing the procedure. ICD-10 codes need to be entered on the claim form. ICD-10 is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO).

## **APC (Ambulatory Payment Classification)**

In most cases, the unit of payment under the HOPPS is the APC. CMS assigns individual services HCPCS & CPT codes to APCs based on similar clinical characteristics and similar costs. The payment rate and copayment calculated for an APC apply to each service within the APC.

## **NDC (National Drug Code)**

An NDC code provides a unique identifier for a specific drug. The NDC for LUMASON ultrasound enhancing agent is: 00270-7099-16.

## **Medicare Addendum B**

These files are updated quarterly and reflect hospital HOPPS payment rates for HCPCS codes and APC codes. [www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files](http://www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files).

## **Medicare Part B ASP (average selling price) file**

Quarterly payment files are published for Independent Diagnostic Testing Facilities (IDTFs) and physician offices. This is where the payment value for LUMASON (Q9950) can be found: [www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html).

## **Medicare Physician Fee Schedule (MPFS)**

Find out physician payment for specific geographic locations in the country for different procedures. This schedule provides: global (G), technical (TC), and professional (26) component payment rates. To find out more information on specific locations visit: [www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSLookup/index.html?redirect=/pfslookup](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSLookup/index.html?redirect=/pfslookup).

**Q9950<sup>2</sup>:** LUMASON ultrasound enhancing agent (UEA)

1 vial = 5 mL

Billing unit is per mL, not by vial or doses

**Medicare Patients:** LUMASON UEA is part of a bundled payment under HOPPS and not separately reimbursed. Please code separately with the echocardiography and radiology procedure codes.

**Commercially Insured Patients:** The provider must contact their respective insurance providers to include Q9950 and establish a reimbursement value.

**Medicaid Patients:** Medicaid coverage varies by state, please consult your local Medicaid office to find the policies in your area. Bracco does not participate in the Medicaid rebate program.

**Procedure Codes:** Echocardiography: 933xx series and C-8921-30 code series.<sup>2,3</sup> Please see page 8 and 9 for a complete list.

**Please note that C-codes series is for HOPPS only and generally for Medicare patients.**







# MEDICARE NATIONAL AVERAGE PAYMENT RATES

## Echocardiography: C-codes

HCPCS code <sup>3</sup>	Long-description HCPCS	2024 HOPPS National Payment Rate <sup>5</sup>
<b>C8921</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete	\$763.67
<b>C8922</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study	\$763.67
<b>C8923</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography	\$763.67
<b>C8924</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study	\$366.80
<b>C8925</b>	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report	\$763.67
<b>C8926</b>	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report	\$763.67
<b>C8927</b>	Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real-time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis	\$763.67
<b>C8928</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report	\$763.67
<b>C8929</b>	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	\$763.67
<b>C8930</b>	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision	\$763.67

## Echocardiography: Cross Walk Codes Without and With Contrast<sup>2,3</sup>

CPT®	Without contrast   With contrast	C-code	CPT	Without contrast   With contrast	C-code
93303	←→	C8921	93312	←→	C8925
93304	←→	C8922	93315	←→	C8926
93306	←→	C8929	93318	←→	C8927
93307	←→	C8923	93350	←→	C8928
93308	←→	C8924	93351	←→	C8930



# MEDICARE NATIONAL AVERAGE PAYMENT RATES FOR HOPPS (cont'd)

## Echocardiography CPT® codes<sup>2</sup> for adult and pediatric patients

CPT code <sup>2</sup>	Long-description CPT	2024 HOPPS National Payment Rate <sup>5</sup>
<b>93303</b>	Transthoracic echocardiography for congenital cardiac anomalies; complete	\$526.17
<b>93304</b>	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	\$526.17
<b>93306</b>	Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	\$526.17
<b>93307</b>	Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography	\$233.71
<b>93308</b>	Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study	\$233.71
<b>93312</b>	Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report	\$526.17
<b>93313</b>	Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); placement of transesophageal probe only	\$526.17
<b>93314</b>	Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); image acquisition, interpretation and report only	Packaged
<b>93315</b>	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report	\$526.17
<b>93316</b>	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	\$526.17
<b>93317</b>	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only	Packaged
<b>93318</b>	Echocardiography, transesophageal (TEE) for monitoring purposes, including probe placement, real-time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis	\$526.17
<b>93350</b>	Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report	\$526.17
<b>93351</b>	Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional	\$526.17
<b>93352</b>	Use of echocardiographic contrast agent during stress echocardiography (List separately in addition to code for primary procedure) (Do not report 93352 more than once per stress echo cardiogram) (Use 93352 in conjunction with 93350, 93351)	Not paid under OPps
<b>93355</b>	Echocardiography, transesophageal (TEE) for guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (eg, tavr, transcatheter pulmonary valve replacement, mitral valve repair, paravalvular regurgitation repair, left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural), real-time image acquisition and documentation, guidance with quantitative measurements, probe manipulation, interpretation, and report, including diagnostic transesophageal echocardiography and, when performed, administration of ultrasound contrast, doppler, color flow, and 3d	Packaged
<b>93320</b>	Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (list separately in addition to codes for echocardiographic imaging); complete	Packaged
	Add-on code, use 93320 in conjunction with 93303, 93304, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8925, C8926, C8928, C8930	
<b>93321</b>	Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (list separately in addition to codes for echocardiographic imaging); follow-up or limited study (list separately in addition to codes for echocardiographic imaging)	Packaged
	Add-on code, use 93321 in conjunction with 93303, 93304, 93308, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8924, C8925, C8926, C8928, C8930	
<b>93325</b>	Doppler echocardiography color flow velocity mapping (list separately in addition to codes for echocardiography)	Packaged
	Add-on code, use 93325 in conjunction with 76825, 76826, 76827, 76828, 93303, 93304, 93308, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8924, C8925, C8926, C8928, C8930	
<b>+93356</b>	Myocardial strain imaging using speckle tracking derived assessment of myocardial mechanics	Packaged

# MEDICARE NATIONAL AVERAGE PAYMENT RATES FOR HOPPS (cont'd)

## Radiology – Liver and Urinary Tract

### Ultrasonography of the liver and urinary tract for vesicoureteral reflux<sup>2</sup>

CPT® code	Description	2024 HOPPS National Payment Rate <sup>5</sup>
76978	Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion	\$175.24
+76979, add-on code	Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)	Packaged

## Alternate Coding from the American Medical Association

### Ultrasonography of the urinary tract for vesicoureteral reflux<sup>4</sup>

CPT® code	Description	2024 HOPPS National Payment Rate <sup>5</sup>
51600	Injection procedure for cystography or voiding urethrocytography	
74455	Urethrocytography, voiding, radiological supervision and interpretation	\$233.71
74430	Cystography, minimum of 3 views, radiological supervision and interpretation	\$366.80

## LUMASON® Ultrasound Enhancing Agent



Note: LUMASON UEA must be coded separately

HCPCS code <sup>3</sup>	Description
Q9950	Sulfur hexafluoride lipid microspheres, per mL; there are 5 mL per single-use vial of LUMASON UEA.

## Hospital in-patient billing: Medicare Severity Adjusted Diagnosis Related Groups (MS-DRG)<sup>6</sup>

ICD-10-PCS procedure codes are used for in-patient billing. They indicate the surgical and/or diagnostic procedures performed on the patient. These codes, in combination with diagnosis codes, help determine the assignment to an MS-DRG payment category under Medicare and other payment systems. Payment in the hospital is determined by the MS-DRG. Under this system, a hospital is paid at a predetermined specific rate for each Medicare discharge. Fixed reimbursement is established for hospital services based on the patient diagnosis and is paid regardless of the actual cost the hospital incurs in providing the services. Ultrasound exams and contrast agents are part of the MS-DRG payment.

## Coverage: Medicare National Coverage Decisions (NCD)

Echocardiography is included in the Medicare NCD for ultrasound and is limited.  
There are Medicare Local Coverage Decisions (LCDs) for echocardiography with contrast.

The echocardiography LCDs can be found on the CMS website at:

<https://www.cms.gov/medicare-coverage-database/search.aspx>.

The Medicare National Coverage Determination (NCD) for ultrasound is non-specific.  
Abdominal and retroperitoneal ultrasound are covered if medically appropriate.

Medicare National Coverage Determinations Manual, Chapter 1, Part 4, Section 220.5

[https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/ncd103c1\\_Part4.pdf](https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/ncd103c1_Part4.pdf)



## All-inclusive portable kit

Each kit contains:

- One LUMASON® vial of 25 mg lipid-type A white lyophilized powder with headspace fill of 60.7 mg of sulfur hexafluoride
- One prefilled syringe containing 5 mL of 0.9% Sodium Chloride Injection, USP (Diluent)
- One Mini-Spike

Product	LUMASON UEA
SKU	709916
NDC	0270-7099-16
Product Description	KIT LUMASON 5x 25MG FLIPCAP
Product Configuration	Five (5) Vial Kit

Novaplus®	SKU 709700	NDC 0270-7099-73
-----------	------------	------------------



## 20-vial pack

Each pack contains:

- Twenty (20) LUMASON® vials of 25 mg lipid-type A white lyophilized powder with headspace fill of 60.7 mg of sulfur hexafluoride
- Twenty (20) Mini-Spikes
- Twenty (20) peel-off syringe labels

Product	LUMASON UEA
SKU	709707
NDC	0270-7097-07
Product Description	MP LUMASON 20x 25MG VIAL/SPIKE US
Product Configuration	Twenty (20) Vial Pack

Novaplus®	SKU 709708	NDC 0270-7097-08
-----------	------------	------------------

Available to purchase direct from Bracco Diagnostics Inc. and through authorized wholesale distributors.  
Novaplus is a registered trademark of Vizient, Inc.

**Customer Service: 1-877-BRACCO 9 (1-877-272-2269)**

### How we support you

The Bracco Reimbursement Hotline is here to support you for all your reimbursement needs.

Ask coding and billing questions regarding Bracco Diagnostics products and procedures related to those products.

- ✓ HCPCS codes for products
- ✓ CPT® and HCPCS codes for procedures
- ✓ Medicare payments
- ✓ Monday-Friday: 9:00 AM-6:00 PM Eastern Time

For more information on reimbursement, contact the Bracco Reimbursement Hotline at:



**1-800-349-1388**




**[askbracco@reimbursement.bracco.com](mailto:askbracco@reimbursement.bracco.com)**

**Please visit us at [www.braccoreimbursement.com](http://www.braccoreimbursement.com) for more information**

### On our website, you may sign up to:

- ✓ Receive educational emails
- ✓ Access our complimentary reimbursement webinars
- ✓ Get the latest updates on:
  - Coding
  - Coverage
  - Payment



1. LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. [Full Prescribing Information](#). Monroe Twp, NJ: Bracco Diagnostics Inc., August 2021.
2. American Medical Association. *2024 Professional Edition CPT® Current Procedural Terminology*. Chicago, IL: American Medical Association; 2023: 416, 546, 563, 792-794.
3. American Medical Association. *HCPCS Level II Professional 2021*. Chicago IL: American Medical Association; 2020: 147-148, 151, 397.
4. American College of Radiology: The Coding Source, May-June 2019 <https://www.acr.org/Advocacy-and-Economics/Coding-Source/May-June-2019/QandA-Voiding-Urosonography>. Published June 24, 2019, Accessed November 20, 2023.
5. Hospital Outpatient Prospective Payment- Notice of Final Rulemaking (NFRM) with Comment Period Year 2024. Medicare Program: Hospital Outpatient Prospective Payment- Notice of Final Rulemaking CM#-1786-FC. <https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices/cms-1786-fc> - Addendum B
6. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Washington, DC: Centers for Medicare & Medicaid Services, Department of Health and Human Services. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c03.pdf>. Published August 2023. Accessed November 20, 2023.

Bracco Diagnostics Inc.  
259 Prospect Plains Road, Building H  
Monroe Township, NJ 08831 USA  
Phone: 609-514-2200  
Toll-Free: 1-877-272-2269 (U.S. only)  
Fax: 609-514-2446

© 2024 Bracco Diagnostics Inc. All Rights Reserved. US-LUM-2300024 01/24

**UNLOCKING THE  
INVISIBLE**

